EVH

AI Memo

Evolent Health

As of 2026-07-28/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-28 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 earnings release scheduled • 2026-08-06

Expected move: +2%

Biggest risk

The key counterweight is weaker profitability and elevated medical-cost pressure; execution or regulatory delays could prevent contracted opportunities from translating into growth.

Invalidation

Break below $3 or thesis failure.

What would change my mind?

Successful oncology and payer expansions, regulatory approvals, and improving demand for complex specialty-care solutions could support substantial upside from the $3.81 anchor.

Research note

Recommendation

—

Confidence

medium

As of

2026-07-28

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Margin and medical-cost reset risk
Oncology and payer expansion execution
Successful oncology and payer expansions, regulatory approvals, and improving demand for complex specialty-care solutions could support substantial upside from the $3.81 anchor.

BearKey bullets

Forward visibility beyond announced launches and the next earnings event is limited.
Low coverage and unavailable analyst-count data reduce confidence in the target-price signal.
Medical-cost pressure and margin compression could persist.

WatchKey bullets

Q2 2026 earnings release scheduled

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $4 (p=50%)

Bull/Bear spread: +62% / -26%

Vs latest close: Bull +62% · Base +2% · Bear -26%

Scenario probabilities

Bull Target: $6 (p=25%)Base Target: $4 (p=50%)Bear Target: $3 (p=25%)

Commentary

Primary-source evidence is strong, but coverage is low and social/options/short-interest data are unavailable. The setup is cautiously constructive because of announced oncology and payer opportunities, offset by margin and medical-cost uncertainty. The August 6 earnings event is the main near-term test; analyst revisions and post-print market reaction are unavailable.

As of 2026-07-28 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Successful oncology and payer expansions, regulatory approvals, and improving demand for complex specialty-care solutions could support substantial upside from the $3.81 anchor.

Bear Case

The key counterweight is weaker profitability and elevated medical-cost pressure; execution or regulatory delays could prevent contracted opportunities from translating into growth.

Drivers

Scannable catalysts and supporting factors

Margin and medical-cost reset risk
Oncology and payer expansion execution

Scenarios

Bull Target (Scenario probability)

$6 / p=25% prob

Base Target (Scenario probability)

$4 / p=50% prob

Bear Target (Scenario probability)

$3 / p=25% prob

Price $4 as of 2026-07-28

Nearest Scenario: Base (∆ 2%)

Targets vs latest close: Bull +62% · Base +2% · Bear -26%

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-06
Q2 2026 earnings release scheduled
Evolent announced it will release second-quarter 2026 results before market open on August 6, 2026, followed by a conference call. The print should clarify revenue execution, margins, medical-cost pressure, and progress on planned launches [#PR-EARNINGS-2026-07-08].
Prob 100.00% • Move 10.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Margin and medical-cost reset risk
2026-08-06
Q1 revenue increased year over year, but adjusted EBITDA and margin declined while the medical expense ratio rose materially. Further deterioration or cautious commentary in Q2 could pressure the shares [#SEC-8K-2026-05-07].
Prob 55% • Move -15% • Priced-in 25%

Long-term Catalysts

Months to a year

Oncology and payer expansion execution
2027-07-28
Q1 materials cited successful on-time oncology launches at Highmark and Aetna, a planned advanced-imaging launch covering approximately 4.5 million lives, and a payer expansion expected to generate more than $200 million of annual revenue, subject to regulatory approvals [#SEC-8K-2026-05-07].
Prob 60% • Move 18% • Priced-in 30%

Risks

Forward visibility beyond announced launches and the next earnings event is limited.
Low coverage and unavailable analyst-count data reduce confidence in the target-price signal.
Medical-cost pressure and margin compression could persist.
Regulatory approvals or launch delays could defer expected revenue.
The company remains loss-making on the cited Q1 results.

Peers

No peer data

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-28

AI Stock Memo: EVH - Evolent Health - RankAlpha